I've tried to capture some of the most interesting responses we've gotten over the past few days since we published our 2012 report.
Celldex Therapeutics ($CLDX) has unveiled overall survival data from a 65-person Phase II trial of the company's brain cancer vaccine rindopepimut. In the single-arm trial, the Needham, MA-based
Biotech stocks were rocked last week when Dendreon, which makes the only approved cancer vaccine, reported that sales of Provenge significantly missed their mark. Dendreon lost two-thirds of its